Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium

Objective: The aim of this study was to determine whether immunohistochemical analysis of molecular parameters can provide an alternative method for classification of endometrial cancer cases according to their aggressiveness.

Methods: Sixty-four cases of endometrial carcinoma were assigned to three groups: group I--28 cases of endometrioid well and moderately differentiated (G1-G2) carcinoma; group II--14 cases of endometrioid poorly differentiated (G3) carcinoma; group III--22 cases of serous papillary endometrial cancer. Immunohistochemistry was used to determine the existence of estrogen receptors (ER), progesterone receptors (PR), and the expression of bcl-2, p53, HER-2/neu and Ki-67.

Results: There was a significant difference in the immunohistochemical profile of the studied molecular parameters comparing the three study groups. The endometrioid G1-G2 cases (group I) were characterized by increased immunoreactivity for ER and PR (85.7% and 78.6%, respectively), increased immunoreactivity for bcl-2 (42.8%) and low expression of p53 (14.3%) and HER-2/neu (14.3%). In contrast to group I cases, the serous papillary endometrial cancer cases (group III) were characterized by immunonegativity for ER, PR and bcl-2 and high immunoreactivity for p53 (81.8%) and HER-2/neu (45.4%). The endometrioid G3 cases (group II) demonstrated an intermediate immunoprofile, characterized by immunonegativity for ER, PR and HER-2/neu, low immunoreactivity for bcl-2 (7.1%) and high expression of p53 (57.1%). The expression of Ki-67 did not differ significantly comparing the different cases of endometrial cancer.

Conclusion: This study provides evidence that the immunohistochemical analysis of endometrial carcinoma differentiates between different grades and histological types, thus being useful in the distinction of high risk cases.

Endometrioid carcinoma of endometrium; Serous papillary carcinoma of endometrium; Grade; Immunohistochemistry; Molecular markers.

[1] Bokhman J. V.: "Two pathogenetic types of endometrial carcinoma". Gynecol. Oncol., 1983, 15, 10.

[2] Sherman M. E., Bur M. E., Kurman R. J.: "p53 in endometrial cancer and its putative precursors: Evidence for diverse pathways oftumorigenesis". Hum. Pathol., 1995, 26, 1268.

[3] Deligdish L., Holinka C. F.: "Progesterone receptors in two groups of endometrial carcinoma". Cancer, 1986, 57, 1385.

[4] Ehlich C. E., Young P. C. M., Stehman F. B., Sutton G. P., Alford W. M.: "Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium". Am. J. Obstet. Gynecol., 1988, 158, 796.

[5] Lax S. F., Pizer E. S., Ronnett B. M., Kurman R. J.: "Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression". Hum. Pathol., 1998, 29, 551.

[6] Zheng W., Cao P., Zheng M., Kramer E. E., Godwin T. A.: "p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes". Gynecol. Oncol., 1996, 61, 167.

[7] Giatromanolaki A., Sivridis E., Koukourakis M. I., Harris A. L., Gatter K. C.: "Bcl-2 and p53 expression in stage I endometrial carcinoma". Anticancer Res., 1998, 18, 3689.

[8] Kohler M. F., Berchuck A., Davidoff A. M., Humphrey P. A., Dodge R. K., Iglehart J. D. et al.: "Overexpression and mutation of p53 in endometrial carcinoma". Cancer Res., 1992, 52, 1622.

[9] Tashiro H., Isacson C., Levine R., Kurman R. J., Cho K. R., Hedrick L.: "p53 g ene mutat10ns are common m utenne serous carcinoma and occur early in their pathogenesis". Am. J. Pathol., 1997, 150, 177.

[10] Nielsen A., Nyholm H. C.: "p53 protein and C-erbB-2 protein (p 185) expression in endometrial adenocarcinoma of endometrioid type". Am. J. Clin. Pathol., 1994, 102, 76.

[11] Khalifa M. A., Mannel R. S., Haraway S. D., Walker J., Min K. W.: "Expression of EGFR, HER-2/neu, p53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas". Gynecol. Oncol., 1994, 53, 84.

[12] Reinartz J. J., George E., Lindgren B. R., Niehans G. A.: "Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival". Hum. Pathol., 1994, 25, 1075.

[13] Salvesen H. B., Iversen 0. E., Akslen L. A.: "Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas". Clin. Cancer. Res., 1998, 4, 2779.

[14] Creasman W. T.: "Prognostic significance of hormone receptors in endometrial cancer". Cancer, 1993, 71, 1467.

[15] Nyholm H. C., Christensen I. J., Nielsen A. L.: "Progesterone receptor levels independently predict survival in endometrial adenocarcinoma". Gynecol. Oncol., 1995, 59, 347.

[16] Lukes A. S., Kohler M. F., Pieper C. F., Kerns B. J., Bentley R., Rodriguez G. C. et al.: "Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer". Cancer, 1994, 73, 2380.

[17] Pisani A. L., Barbuto D. A., Chen D., Ramos L., Lagasse L. D., Karlan B. Y.: "HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma". Obstet. Gynecol., 1995, 85, 729.

[18] Soong R., Knowles S., Williams K. E., Hammond I. G., Wysocki S. J., Iacopetta B. J.: "Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma". Br. J. Cancer, 1996, 74, 562.

[19] Heffner H. M., Freedman A. N., Asirwatham J. E., Lele S. B.: "Prognostic significance of p53, PCNA, and c-erbB-2 in endometrial adenocarcinoma". Eur. J. Gynaecol. Oncol., 1999, 20, 8.

[20] Gassel A. M., Backe J., Krebs S., Schon S., Caffier H., MullerHermelink H. K.: "Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long-term outcome". J. Clin. Pathol., 1998, 51, 25.

[21] Geisler J.P., Wiemann M. C., Zhou Z., Miller G. A., Geisler H. E.: "Proliferation index determined by MIB-1 and recurrence in endometrial cancer". Gynecol. Oncol., 1996, 61, 373.

[22] Scully R. E., Bonfiglio T. A., Kurman R. J.: "Histopathological typing of the female genital tract tumours". In: Sobin L. (ed): World Health Organization International Histological Classification of Tumours (ed. 2), Berlin, Germany, Springer Verlag, 1994.

[23] Kurman R. J., Zaino R. J., Norris H.J.: "Endometrial carcinoma in Blausteins's Pathology of the F emale Genital Tract". (Kurman R. J., Ed.) Springer-Verlag, New York, 4" ed., 1994, 439.

[24] Announcements FIGO stages - 1988 revision. Gynecol. Oncol., 1989, 35, 125.

[25] Pertschuk L. P., Masood S., Simone J., Feldman J. G., F ruchter R., Axiotis C. A., Greene G. L.: "Estrogen receptor immunocytochemistry in endometrial carcinoma: A prognostic marker for survival". Gynecol. Oneal., 1996, 63, 28.

[26] Fukuda K., Mori M., Uchiyama M., Iwai K., Iwasaka T., Sugimori H.: "Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma". Gynecol. Oneal., 1998, 69, 220.

[27] Henderson G. S., Brown K., Abbott T., Perkins S. L., Clayton F.: "Bcl-2 expression is down-regulated in atypical endometrial hyperplasia and adenocarcinoma". Mod. Pathol., 1995, 8, 90a.

[28] Miturski R., Semczuk A., Tomaszewski J.,J akowicki J.: "bcl-2 protein expression in endometrial carcinoma: the lack of correlation with p53". Cancer Letters, 1998, 133, 63.

[29] Taskin M., Lallas T. A., Barber H. R. K., Shevchuk: "bcl-2 and p53 in endometrial adenocarcinoma". Mod. Pathol., 1997, 10, 728.

[30] Saegusa M., Kamata Y., Isono M., Okayasu J.: "Bcl-2 expression is correlated with a low apoptotic index and associated with progesterone receptor immunoreactivity in endometrial carcinomas". J. Pathol., 1996, 180, 275.

[31] Powell B., Soong R., Grieu F., Knowles S., Hammond I., Iacopetta B.: "p53 protein overexpression is a prognostic indicator of poor survival in stage I endometrial carcinoma". Int. J. Oncol., 1999, 14, 175.

[32] Berchuck A., Kohler M. F., Marks J. R., Wiseman R., Boyd J., Bast R. C. Jr.: "The p53 tumor suppressor gene frequently is altered in gynecologic cancers". Am. J. Obstet. Gynecol., 1994, 170, 246.

[33] Honda T., Kato H., Imamura T., Gima T., Nishida J. I., Sasaki M. et al.: "Involvemertt of p53 gene mutations in human endometrial carcinoma". Int. J. Cancer, 1993, 53, 963.

[34] Saegusa M., Okayasu I.: "bcl-2 is closely correlated with favorable prognostic factors and inversely associated with p53 protein accumulation in endometrial carcinomas: immunohistochemical and polymerase chain reaction/loss of heterozygosity findings". J. Cancer Res. Clin. Oneal., 1997, 123, 429.

[35] Chhieng D. C., Ross J. S., Ambros R. A.: "bcl-2 expression and the development of endometrial carcinoma". Mod. Pathol., 1996, 9, 402.

[36] Gullick W. J.: "The role of the epidermal growth factor receptor and the c-erb-2 protein in breast cancer". Int. J. Cancer (Suppl.), 1990, 5, 55.

[37] Slarnon D. J., Godolphin W.,J ones L. A.,H olt J. A.,W ong S. G., Keith D. E. et al.: "Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer". Science, 1989, 244, 707.

[38] Berchuk A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R. et al.: "Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer". Cancer Res., 1990, 50, 4087.

[39] Hetzel D. J., Wilson T. 0., Keeney G. L., Roche P. C., Cha S. S., Podratz K. C.: "HER-2/neu expression: a major prognostic factor in endometrial cancer". Gynecol. Oncol., 1992, 47, 179.

[40] Gerdes J., Li L., Schluter C., Duchrow M., Wohlenberg C., Gerlach C., Stahmer I., Kloth S., Brandt E., Flad H. D.: "Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67". Am. J. Pathol., 1991, 138, 867.

[41] Cattoretti G., Becker M. H., Key G., Duchrow M., Schluter C., Galle J., Gerdes J.: "Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB I and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections". J. Pathol., 1992, 168, 357.

[42] Salvesen H. B., Iversen 0. E., Akslen L. A.: "Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas". Clin. Cancer Res., 1998, 4, 2779.